Literature DB >> 18428322

Construction of replication-defective herpes simplex virus vectors.

William F Goins1, Peggy Marconi, David Krisky, Darren Wolfe, Joseph C Glorioso, Ramesh Ramakrishnan, David J Fink.   

Abstract

Advances in identification and characterization of gene products responsible for specific diseases of the nervous system have opened opportunities for novel therapies using gene transfer vectors for gene replacement. Herpes simplex virus (HSV)-based vectors are particularly well suited for gene delivery to neurons of the central and peripheral nervous systems. The authors have developed methods to delete HSV-1 IE gene functions and to subsequently introduce foreign genes into the HSV-1 genome using homologous recombination. This unit describes methods for generating cell lines that complement multiple essential gene deletion mutants as well for generating such replication-defective virus recombinants and inserting foreign DNA sequences into replication-defective viral genomes, the last step in preparing a vector. Three support protocols describe methods for preparing virus stocks, titering virus, and preparing viral DNA.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 18428322     DOI: 10.1002/0471142905.hg1211s33

Source DB:  PubMed          Journal:  Curr Protoc Hum Genet        ISSN: 1934-8258


  3 in total

1.  Extreme susceptibility of African naked mole rats (Heterocephalus glaber) to experimental infection with herpes simplex virus type 1.

Authors:  James Artwohl; Susan Ball-Kell; Tibor Valyi-Nagy; Steven P Wilson; Ying Lu; Thomas J Park
Journal:  Comp Med       Date:  2009-02       Impact factor: 0.982

2.  Herpes simplex virus type 1 vector-mediated expression of nerve growth factor protects dorsal root ganglion neurons from peroxide toxicity.

Authors:  W F Goins; K A Lee; J D Cavalcoli; M E O'Malley; S T DeKosky; D J Fink; J C Glorioso
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

Review 3.  Herpes simplex virus-based nerve targeting gene therapy in pain management.

Authors:  James R Goss; David Krisky; James Wechuck; Darren Wolfe
Journal:  J Pain Res       Date:  2014-01-20       Impact factor: 3.133

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.